Nilotinib hydrochloride monohydrate(CAS: 923288-90-8)

Nilotinib hydrochloride monohydrate is a crystalline solid with a molecular weight of approximately 467.8 g/mol. It is sparingly soluble in water and ethanol. The compound shows moderate reactivity with bases and is stable under normal storage conditions. Good solubility in organic solvents like methanol and acetonitrile makes it suitable for pharmaceutical applications.

Nilotinib hydrochloride monohydrate is synthesized through a multi-step process involving condensation reactions, hydrogenation, and hydrochloric acid treatment. The key steps include the conversion of an intermediate to the target compound, followed by hydrochloridation and crystallization. The process typically yields 85-90% purity with high selectivity.

Nilotinib hydrochloride monohydrate is primarily used in the pharmaceutical industry for the treatment of chronic myeloid leukemia. It is also of interest in research for its kinase inhibitory properties, making it relevant to the development of targeted cancer therapies. Further applications are being explored in the field of drug discovery and personalized medicine.

When handling Nilotinib hydrochloride monohydrate, it is essential to use personal protective equipment (PPE) such as gloves, goggles, and a lab coat. Work in a well-ventilated area or fume hood to avoid inhalation. Spills should be immediately cleaned up using appropriate absorbent materials, and the area should be thoroughly washed down. Refer to the Safety Data Sheet (SDS) for detailed handling and disposal instructions.